Abatacept

Active ingredient description

Abatacept is a fusion protein that consists of the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) linked to a modified Fc portion of human immunoglobulin G1 (IgG1). Abatacept selectively modulates a key costimulatory signal required for full activation of T lymphocytes expressing CD28.

Medicine classification

This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:

ATC code
Group title
Classification
Abatacept
L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AA Selective immunosuppressants
Discover more medicines within L04AA24

Medicines

Abatacept is the active ingredient of these drugs:

Drug
Countries

Australia Austria Brazil Canada Cyprus

Product monographs

Medicine agencies around the world have authorized marketing of this active ingredient according to these medication package inserts (MPIs):

Title
Type
Country
Summary of Product Characteristics (SPC)
Summary of Product Characteristics (SPC)

Unique ingredient identifier (UNII)

7D0YB67S97 - ABATACEPT

CAS registry number

332348-12-6 - abatacept

SNOMED-CT

421777009 - Abatacept (substance)